Plasma disposition of clindamycin microbiological activity in cats after single oral doses of clindamycin hydrochloride as either capsules or aqueous solution

Journal of Veterinary Pharmacology and Therapeutics

Volumn 19, Issue 6, 1996, Pages 491-494

  Boothe, D M ^a   Brown, S A ^b   Fate, G D ^b   Pierce, P A ^b   Hanson, B J ^b   Al Adhami, M ^b   Boothe, H W ^a   Howe, L B ^c   Nguyen, J ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b PFIZER INC   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN;

ANIMAL EXPERIMENT; ANTIMICROBIAL ACTIVITY; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; CAT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DISPOSITION; DRUG HALF LIFE; FEMALE; MALE; MEAN RESIDENCE TIME; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ANIMALIA; FELIS CATUS;

EID: 0030443051     PISSN: 01407783     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2885.1996.tb00088.x     Document Type: Article

References (14)

1. Aucoin, D. (1993) Target: The Antimicrobial Reference Guide to Effective Treatment. p. 83. North American Compendium Inc, Port Huron, MI, USA.
2. Berg, J.N., Scanlan, C.M., Buening, G.M., Fales, W.H., Schmidt, D.A. & Wilson, J.C. (1984) Clinical models for anaerobic bacterial infections in dogs and their use in testing the efficacy of clindamycin and lincomycin. American Journal of Veterinary Research, 45, 1299-1306.
3. Braden, T.D., Johnson, C.A., Gabel, C.L., Lott, G.A. & Caywood, D.D. (1987). Posologic evaluation of clindamycin, using a canine model of postraumatic osteomyelitis. American Journal of Veterinary Research, 48, 1101-1105.
4. Braden, T.D., Johnson, C.A., Wakenell, P., Tvedten, H.W. & Mostosky, U.V. (1988). Efficacy of clindamycin in the treatment of Staphyloccus aureus osteomyelitis in dogs. Journal of the American Veterinary Medical Association, 192, 1721-1725.
5. Brown, S.A., Dieringer, T.M., Hunter, R.P. & Zaya M.J. (1989) Oral clindamycin disposition after single and multiple doses in normal cats. Journal of Veterinary Pharmacology and Therapeutics, 12, 209-216.
6. Gibaldi, M. & Perrier, D. (1982) Pharmacokinetics. pp 445-450. Marcel Dekker, New York.
7. Green, C.G., Cook, J.R., & Mahaffey, EA. (1985) Clindamycin for treatment of Toxoplasma polymyositis in a dog. Journal of the American Veterinary Medical Association, 187, 631-634.
8. Hart, L.L. (1992) Clindamycin in the treatment of toxoplasmosis in AIDS. Annals of Pharmacotherapy, 26, 645-649.
9. Henke, C.L., Barbiers, A.R., Smith L.J., Lallinger, A.J., Bell, R.L. & Baird, G.M. (1987) A single dose crossover study comparing clindamycin serum bioactivity in canines after administration of clindamycin HCl oral solution and clindamycin HCl capsules. Upjohn Technical Report No. 774-9690-80-001. Revised 2 June 1987.
10. Thomas, R.C., Lummis, W.L. & Harpootlian H. (1970) Comparative absorption and excretion of clindamycin (U-21,251F) and clindamycin-2-palmitate (U-26,179E) in the dog. Upjohn Technical Report No. 6102/70/7261/019. 12 October 1970.
11. Townsend, R.J. & Baker, R.P. (1987) Pharmacokinetic comparison of three clindamycin phosphate dosing schedules. Annals of Pharmacology, 21, 279-281.
12. Weber, D.J. (1977) A retrospective analysis of clindamycin dosage regimen in dogs. Upjohn Technical Report No. 7254/77/7261/001. 17 November 1977.
13. R in dogs. Upjohn Technical Report No. 7254/78/7261/001. 16 March 1978.
14. Yamoaka, K., Nakagawa, T. & Uno, T. (1978) Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. Journal of Pharmacokinetics and Biopharmaceutics, 6, 165-175.